

Titolo	Studio di fase 3, in aperto, randomizzato per confrontare l'efficacia e la sicurezza di odronextamab (REGN1979), un anticorpo bispecifico Ant-CD20 x Anti-CD3 in combinazione con chemioterapia rispetto a rituximab in combinazione con chemioterapia in partecipanti con linfoma follicolare precedentemente non trattati
Codice studio	OLYMPIA-2
Patologia:	Linfoma follicolare
Tipo di Studio:	interventistico
Tipologia	profit
Fase:	3
Principali criteri di inclusione:	<ul style="list-style-type: none"> <li>• Have diagnosis of CD20+ FL grade 1-3a, stage II bulky or stage III / IV</li> <li>• previously untreated participants who have FLIPI-1 score of 0 to 5</li> <li>• Have measurable disease (defined as at least 1 bidimensionally measurable nodal lesion of &gt;1.5 cm or extranodal disease of &gt;1 cm in the greatest transverse diameter)</li> <li>• Calculated creatinine clearance by Cockcroft-Gault formula <math>\geq 50</math> mL/min</li> </ul>
Principali criteri di esclusione:	<ul style="list-style-type: none"> <li>• Participants with central nervous system lymphoma or leptomeningeal lymphoma</li> <li>• Participants with histological evidence of transformation to a high-grade or diffuse large B- cell lymphoma</li> <li>• Treatment with any systemic anti-lymphoma therapy</li> <li>• Standard radiotherapy within 14 days of first administration</li> </ul>
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it